Leading specialists in pulmonology have formed Healio Pulmonology’s Peer Perspective Board to help guide coverage and provide ...

Q1 2025 Results Conference Call April 23, 2025 6:30 AM ETCompany ParticipantsTuukka Hirvonen - Head of IRLiisa Hurme ...

PHA launched a certificate program for healthcare professionals, providing specialized training for PH diagnosis, treatment, ...

Pulmonary embolism (PE) is a significant cause of morbidity and mortality, particularly in patients classified as acute, ...

Supporters will unite on May 5 to mark World Pulmonary Hypertension Day, with a focus this year on early diagnosis.

Mizuho initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $51 price target The company’s lead asset, TX45, is a ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

A Johns Hopkins Medicine-led analysis of medical information gathered on a diverse group of almost 250,000 people over four years has significantly clarified the link between the "exclusive" use of ...

A Johns Hopkins Medicine-led analysis of medical information gathered on a diverse group of almost 250,000 people over four ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.